Controlling immune cell responses to target diseases
Conditional control of universal antigen receptor signaling
['FUNDING_R01'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-10901896
This study is looking at a new way to improve cancer and autoimmune treatments by changing T cells in your body to better target the specific problems you're facing, so you can have a more effective and personalized treatment with fewer side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-10901896 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing adoptive cell therapy by genetically modifying T cells to express universal antigen receptors. These engineered cells can be programmed to target specific antigens associated with various diseases, including cancers and autoimmune disorders. By using a modular approach, the therapy aims to improve the precision and effectiveness of treatment while minimizing side effects. Patients receiving these modified cells could benefit from a more tailored and effective immune response against their specific conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with blood cancers, solid tumors, or autoimmune diseases who may benefit from targeted immune therapies.
Not a fit: Patients with conditions that do not involve antigen-specific targets or those who are not eligible for cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for cancers and autoimmune diseases.
How similar studies have performed: Previous research has shown promise in using engineered T cells for cancer treatment, indicating that this approach could be a significant advancement in the field.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LOHMUELLER, JASON JAKOB — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: LOHMUELLER, JASON JAKOB
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases